Combinational Therapy Using Nanoadjuvantsas Carriers of HPV۱۶ E۷ Epitope Against CervicalCancer
- سال انتشار: 1402
- محل انتشار: اولین کنگره بین المللی ژنومیک سرطان
- کد COI اختصاصی: CGC01_004
- زبان مقاله: انگلیسی
- تعداد مشاهده: 68
نویسندگان
Student Research Committee, Maragheh University of MedicalSciences, Maragheh, Iran
Department of Medical Biotechnology, Faculity of Maragheh Universityof Medical Sciences, Maragheh, Iran
چکیده
Background: Human papillomavirus (HPV)-induced cervicalcancer is a major health concern in women and therapeuticvaccines can overcome the challenge. Although peptide-basedvaccines are a promising strategy for developing therapeuticvaccines, insufficiency to generate robust immunity limits theirapplication. In the current study, we coated the surface of negatively-charged nanoadjuvants, adenovirus (Ad) and aluminumphosphate (AlPO۴ or Alum), with positively-charged HPV۱۶E۷ epitope to develop an effective combinational regimen withtherapeutic effects on a TC-۱ mouse model.Materials and Methods: To develop an optimal Ad/peptide(Ad/pep) construct, Ads and positively-charged epitopes weremixed at ۱:۱۰۰, ۱:۲۵۰, and ۱:۵۰۰ ratios and their surface chargeand particle size were characterized by zeta potential and dynamiclight scattering. Alum/peptide (Alum/pep) constructsalso were developed by simple mixing of ۲۰ μg of AlPO۴ and۲۰ μg of HPV۱۶ E۷ epitope. The developed constructs wereadministrated into the TC-۱ mouse model according to variousprime-boost vaccination regimens, and finally the levels ofIFN-γ, IL-۱۰, and CTL responses as well as inhibition of tumorgrowth, were measured.Results: Incubation of positively-charged HPV۱۶ E۷ epitopewith Ad and Alum changed the negative charge of nanoadjuvantsto a positive one, without significant changes in their size,indicating that E۷ epitope coated on the surface of nanoadjuvants.Compared with naked nanoadjuvants, homologous administrationof E۷-coated nanoadjuvants exhibited significantanti-tumor activities. Furthermore, we indicated that heterologousregimens, using Ad/Pep-Alum/Pep and Alum/Pep-Ad/Pep, showed superior anti-tumor activities, characterized byhigher levels of IFN-γ, IL-۱۰, and CTL responses, as well asinhibition of TC-۱ tumors in vivo.Conclusion: We introduced a versatile and rapid immunotherapyplatform based on nanoadjuvants and their combinationalregimens that elicits potent anti-tumor immune responses, withoutany genetic engineering processes.کلیدواژه ها
Papillomavirus, Cancer, Nanoadjuvant, Adenovirus,Alumمقالات مرتبط جدید
- بازتاب دانش سنتی و باورهای عامیانه مربوط به محیط زیست در مثل ها و زبانزدهای بختیاری
- سرطان چگونه به وجود می آید؟
- آشنایی با انواع سرطان و علائم آنها، راه های تشخیص و درمان
- Deciphering the Impact of the L۸۵۸R Mutation in EGFR: Computational Insights and Therapeutic Implications in Non-Small-Cell Lung Cancer
- systematic review on Investigating the relationship between obesity and breast cancer in women
اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.